Kuros Biosciences AG
Kuros Biosciences AG Fundamental Analysis
Kuros Biosciences AG (KURN.SW) shows weak financial fundamentals with a PE ratio of 555.84, profit margin of 1.26%, and ROE of 2.28%. The company generates $0.1B in annual revenue with weak year-over-year growth of 1.25%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 52.3/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze KURN.SW's fundamental strength across five key dimensions:
Efficiency Score
WeakKURN.SW struggles to generate sufficient returns from assets.
Valuation Score
WeakKURN.SW trades at a premium to fair value.
Growth Score
ModerateKURN.SW shows steady but slowing expansion.
Financial Health Score
ExcellentKURN.SW maintains a strong and stable balance sheet.
Profitability Score
WeakKURN.SW struggles to sustain strong margins.
Key Financial Metrics
Is KURN.SW Expensive or Cheap?
P/E Ratio
KURN.SW trades at 555.84 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, KURN.SW's PEG of 4.39 indicates potential overvaluation.
Price to Book
The market values Kuros Biosciences AG at 13.60 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 90.45 times EBITDA. This signals the market has high growth expectations.
How Well Does KURN.SW Make Money?
Net Profit Margin
For every $100 in sales, Kuros Biosciences AG keeps $1.26 as profit after all expenses.
Operating Margin
Core operations generate 5.99 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $2.28 in profit for every $100 of shareholder equity.
ROA
Kuros Biosciences AG generates $1.53 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Kuros Biosciences AG generates limited operating cash flow of $-733.28K, signaling weaker underlying cash strength.
Free Cash Flow
Kuros Biosciences AG generates weak or negative free cash flow of $-2.83M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.07 in free cash annually.
FCF Yield
KURN.SW converts -0.31% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
555.84
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
4.39
vs 25 benchmark
P/B Ratio
Price to book value ratio
13.60
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.03
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.06
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.96
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.11
vs 25 benchmark
How KURN.SW Stacks Against Its Sector Peers
| Metric | KURN.SW Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 555.84 | 28.31 | Worse (Expensive) |
| ROE | 2.28% | 699.00% | Weak |
| Net Margin | 1.26% | -130884.00% (disorted) | Weak |
| Debt/Equity | 0.06 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 1.96 | 2775.16 | Neutral |
| ROA | 1.53% | -14469.00% (disorted) | Weak |
KURN.SW outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Kuros Biosciences AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
1262.08%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
84.75%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
113.36%
Industry Style: Defensive, Growth, Innovation
High Growth